Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Suspected non-AD pathology in mild cognitive impairment

Wisse, Laura E M LU orcid ; Butala, Nirali ; Das, Sandhitsu R ; Davatzikos, Christos ; Dickerson, Bradford C ; Vaishnavi, Sanjeev N ; Yushkevich, Paul A and Wolk, David A (2015) In Neurobiology of Aging 36(12). p.3152-3162
Abstract

We aim to better characterize mild cognitive impairment (MCI) patients with suspected non-Alzheimer's disease (AD) pathology (SNAP) based on their longitudinal outcome, cognition, biofluid, and neuroimaging profile. MCI participants (n = 361) from ADNI-GO/2 were designated "amyloid positive" with abnormal amyloid-beta 42 levels (AMY+) and "neurodegeneration positive" (NEU+) with abnormal hippocampal volume or hypometabolism using fluorodeoxyglucose-positron emission tomography. SNAP was compared with the other MCI groups and with AMY- controls. AMY-NEU+/SNAP, 16.6%, were older than the NEU- groups but not AMY- controls. They had a lower conversion rate to AD after 24 months than AMY+NEU+ MCI participants. SNAP-MCI participants had... (More)

We aim to better characterize mild cognitive impairment (MCI) patients with suspected non-Alzheimer's disease (AD) pathology (SNAP) based on their longitudinal outcome, cognition, biofluid, and neuroimaging profile. MCI participants (n = 361) from ADNI-GO/2 were designated "amyloid positive" with abnormal amyloid-beta 42 levels (AMY+) and "neurodegeneration positive" (NEU+) with abnormal hippocampal volume or hypometabolism using fluorodeoxyglucose-positron emission tomography. SNAP was compared with the other MCI groups and with AMY- controls. AMY-NEU+/SNAP, 16.6%, were older than the NEU- groups but not AMY- controls. They had a lower conversion rate to AD after 24 months than AMY+NEU+ MCI participants. SNAP-MCI participants had similar amyloid-beta 42 levels, florbetapir and tau levels, but larger white matter hyperintensity volumes than AMY- controls and AMY-NEU- MCI participants. SNAP participants performed worse on all memory domains and on other cognitive domains, than AMY-NEU- participants but less so than AMY+NEU+ participants. Subthreshold levels of cerebral amyloidosis are unlikely to play a role in SNAP-MCI, but pathologies involving the hippocampus and cerebrovascular disease may underlie the neurodegeneration and cognitive impairment in this group.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
author collaboration
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Aged, Aged, 80 and over, Alzheimer Disease/pathology, Amyloid beta-Peptides/metabolism, Cognition, Cognitive Dysfunction/metabolism, Female, Hippocampus/metabolism, Humans, Male, Memory, Middle Aged, Nerve Degeneration, Neuroimaging, Peptide Fragments/metabolism
in
Neurobiology of Aging
volume
36
issue
12
pages
11 pages
publisher
Elsevier
external identifiers
  • pmid:26422359
  • scopus:84946562079
ISSN
1558-1497
DOI
10.1016/j.neurobiolaging.2015.08.029
language
English
LU publication?
no
additional info
Copyright © 2015 Elsevier Inc. All rights reserved.
id
b70d63c8-1cef-4e85-8784-5570b76fda00
date added to LUP
2024-02-28 14:59:32
date last changed
2024-06-09 06:21:14
@article{b70d63c8-1cef-4e85-8784-5570b76fda00,
  abstract     = {{<p>We aim to better characterize mild cognitive impairment (MCI) patients with suspected non-Alzheimer's disease (AD) pathology (SNAP) based on their longitudinal outcome, cognition, biofluid, and neuroimaging profile. MCI participants (n = 361) from ADNI-GO/2 were designated "amyloid positive" with abnormal amyloid-beta 42 levels (AMY+) and "neurodegeneration positive" (NEU+) with abnormal hippocampal volume or hypometabolism using fluorodeoxyglucose-positron emission tomography. SNAP was compared with the other MCI groups and with AMY- controls. AMY-NEU+/SNAP, 16.6%, were older than the NEU- groups but not AMY- controls. They had a lower conversion rate to AD after 24 months than AMY+NEU+ MCI participants. SNAP-MCI participants had similar amyloid-beta 42 levels, florbetapir and tau levels, but larger white matter hyperintensity volumes than AMY- controls and AMY-NEU- MCI participants. SNAP participants performed worse on all memory domains and on other cognitive domains, than AMY-NEU- participants but less so than AMY+NEU+ participants. Subthreshold levels of cerebral amyloidosis are unlikely to play a role in SNAP-MCI, but pathologies involving the hippocampus and cerebrovascular disease may underlie the neurodegeneration and cognitive impairment in this group.</p>}},
  author       = {{Wisse, Laura E M and Butala, Nirali and Das, Sandhitsu R and Davatzikos, Christos and Dickerson, Bradford C and Vaishnavi, Sanjeev N and Yushkevich, Paul A and Wolk, David A}},
  issn         = {{1558-1497}},
  keywords     = {{Aged; Aged, 80 and over; Alzheimer Disease/pathology; Amyloid beta-Peptides/metabolism; Cognition; Cognitive Dysfunction/metabolism; Female; Hippocampus/metabolism; Humans; Male; Memory; Middle Aged; Nerve Degeneration; Neuroimaging; Peptide Fragments/metabolism}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{3152--3162}},
  publisher    = {{Elsevier}},
  series       = {{Neurobiology of Aging}},
  title        = {{Suspected non-AD pathology in mild cognitive impairment}},
  url          = {{http://dx.doi.org/10.1016/j.neurobiolaging.2015.08.029}},
  doi          = {{10.1016/j.neurobiolaging.2015.08.029}},
  volume       = {{36}},
  year         = {{2015}},
}